The FDA sent warning letters to thirty telehealth companies in early March for what the agency called "false or misleading claims" about compounded GLP-1 medications [1]. The letters targeted firms marketing compounded versions of semaglutide and tirzepatide -- the active ingredients in Ozempic, Wegovy, and Mounjaro -- through online platforms that promised cheaper access to the drugs reshaping American waistlines and pharmaceutical balance sheets.

The agency's position was consumer safety. Compounded drugs, unlike FDA-approved medications, are not subject to the same manufacturing standards, clinical testing, or labeling requirements. The telehealth companies, the FDA argued, were making claims that their compounded products were equivalent to or "the same as" branded medications when they were not [2]. As this paper covered in its earlier reporting, the regulatory machinery was already accelerating in February when the FDA announced its intent to "take decisive steps to restrict GLP-1 active pharmaceutical ingredients" in the compounding supply chain [3].

The timing was convenient for one particular company. On February 9, Novo Nordisk -- the Danish pharmaceutical giant that manufactures Ozempic and Wegovy -- filed a patent infringement lawsuit against Hims & Hers Health in Delaware federal court. The complaint alleged that Hims's compounded semaglutide products infringed Novo's utility patents and constituted "unlawful mass marketing of unapproved versions" of its drugs [4]. Hims had briefly launched a $49 compounded oral semaglutide pill before pulling it under regulatory pressure. Novo sued anyway.

Then something interesting happened. On March 9, Novo Nordisk dropped the lawsuit. The two companies announced a collaboration: Hims would begin distributing FDA-approved Wegovy directly, cutting compounders out of the equation entirely [5]. The lawsuit was not about stopping Hims. It was about converting Hims from a competitor into a distribution channel.

On X, the pattern was immediately legible. The FDA's warning letters and Novo's lawsuit arrived in the same regulatory moment, aimed at the same target -- the compounding pharmacies and telehealth platforms that had built a multibillion-dollar business offering GLP-1 medications at a fraction of the branded price. Semaglutide costs approximately $1,000 per month at branded prices. Compounded versions were available through telehealth platforms for $200 to $400. The price gap was the market. The regulatory action closed the market [6].

MSM covered the warning letters as a straightforward consumer protection story. Reuters reported that the telehealth firms had made "false or misleading claims" -- the FDA's language, adopted without friction [7]. The Pharmacy Times noted the broader enforcement trend, with CDER warning letters up 50 percent year-over-year [8]. The narrative was tidy: unregulated companies making dangerous claims about unregulated drugs, and the FDA stepping in to protect patients.

The narrative on X was less tidy. Compounded medications are legal. They have been part of American pharmacy for decades. The FDA's authority to restrict compounding exists in tension with the practice itself -- pharmacies have broad latitude to compound drugs when commercially manufactured versions are in shortage. GLP-1 drugs were in shortage throughout 2024 and much of 2025. The FDA's February 2026 declaration that the shortage was resolved -- and therefore compounding was no longer justified -- was the regulatory trigger that made the warning letters possible [3].

The question X kept asking was who benefited. Thirty telehealth companies received warning letters. One pharmaceutical company saw its monopoly restored. The answer was not subtle.

For the patients who had been accessing compounded GLP-1 drugs at affordable prices, the outcome was clear: pay branded prices or stop treatment. The FDA would call that safety. Novo Nordisk would call that intellectual property protection. The thirty telehealth companies would call it the end of their business model. The patients would call it expensive.

-- NORA WHITFIELD, Chicago